YN440276 Nocodazole 31430-18-9

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively.

YN440189 Pivanex 122110-53-6

Pivanex (AN-9), a derivative of Butyric acid, is an orally activeHDACinhibitor. Pivanex down-regulatesbcr-ablprotein and enhancesapoptosis. Pivanex has antimetastic and antiangiogenic properties.

YN440321 Imatinib 152459-95-5

Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

YN440003 BCR-ABL-IN-1 188260-50-6

BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia.

YN440411 Imatinib Mesylate 220127-57-1

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, re...

YN440089 PD173955 260415-63-2

PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM.

YN440045 Dasatinib 302962-49-8

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

YN440038 Bosutinib 380843-75-4

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

YN440192 DPH 484049-04-9

DPH is a potent cell permeablec-Ablactivator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation.

YN440307 AST 487 630124-46-8

AST-487,a N,N'-diphenyl urea,is an ATP competitive inhibitor of Flt3 with ki of 0.12 μM.Besides FLT3, AST487 also inhibits RET,KDR,c-KIT,and c-ABL kinase with IC50 values below 1 μM.

YN440039 Nilotinib 641571-10-0

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

YN440135 GNF-2 778270-11-4

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

YN440075 Multi-kinase inhibitor 1 778274-97-8

Multi-kinase inhibitor 1 is a potentmulti-kinaseinhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the ac...

YN440341 GNF-5 778277-15-9

GNF-5 is a selective and allosteric Bcr-Abl inhibitor with IC50 of 220 nM.

YN440046 Dasatinib hydrochloride 854001-07-3

Dasatinib hydrochloride is a potent and dual AblWT/Src inhibitor IC50 of 0.6 nM/0.8 nM respectively; also inhibits c-KitWT/c-KitD816V with IC50 of 79 nM/37 nM.

YN440258 Degrasyn 856243-80-6

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of trans...

YN440406 Bafetinib 859212-16-1

Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Ph...

YN440185 Lyn-IN-1 887650-05-7

Lyn-IN-1 (Bafetinib analog) is a potent and selective dual Bcr-Abl/Lyn inhibitor, extracted from patent WO2014169128A1.

YN440295 Flumatinib 895519-90-1

Flumatinib (HHGV678) is an orally available, selective inhibitor ofBcr-Abl. Flumatinib inhibitsc-Abl,PDGFRβ and c-Kitwith IC50s of 1.2nM, 307.6nM and 665.5nM, respectively.

YN440296 Flumatinib mesylate 895519-91-2

Flumatinib mesylate (HHGV678 mesylate) is an orally available, selective inhibitor ofBcr-Abl. Flumatinib mesylate inhibitsc-Abl,PDGFRβ and c-Kitwith IC50s of 1.2nM, 307.6nM and 665.5nM, respectively.